Trial Profile

A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults with Long COVID

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bezisterim (Primary)
Indications Parkinson's disease
Focus Therapeutic Use
Acronyms ADdRESs-LC
Sponsors BioVie

Most Recent Events

12 Mar 2026 According to a BioVie media release, topline results from this trial are expected in mid-2026.
12 Feb 2026 According to a BioVie media release, company announced the acceptance of abstract from this study on its lead candidate bezisterim (NE3107), in the treatment of Alzheimers Disease and Long COVID at the 2026 American College of Psychiatrists (ACP) annual meeting, to be held February in Bonita Springs, FL.
29 Jan 2026 Planned End Date changed from 1 Jan 2026 to 1 Jun 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com